SynthesisThe Cochrane database of systematic reviews2002
Penicillin for secondary prevention of rheumatic fever.
Synthesis in The Cochrane database of systematic reviews, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 2 syntheses or guidelines pooled it, 228 citations in OpenAlex.
- Long-term antibiotic prophylaxis for prevention of rheumatic fever recurrence and progression to rheumatic heart disease.The Cochrane database of systematic reviews · 2024Pooled it
- Routine Antenatal Echocardiography in High-Prevalence Areas of Rheumatic Heart Disease: A WHO-Guideline Systematic Review.Global heart · 2024Pooled it
- Implementation and evaluation of a pragmatic community streptococcal treatment programme to improve rheumatic heart disease primary prevention in Uganda.BMJ global health · 2026Trial
- Trial
- Efficacy of an incentive intervention on secondary prophylaxis for young people with rheumatic fever: a multiple baseline study.BMC public health · 2019Trial
- Trial
- Acute rheumatic fever and rheumatic heart disease in Latin America: a contemporary review of epidemiology.Lancet regional health. Americas · 2026Review
- Implications for sustaining secondary prophylaxis for rheumatic heart disease in Ethiopia: Uptake and determinants in a multicentre cross-sectional study.PLoS neglected tropical diseases · 2026Article
- A forgotten cause of chest pain in the United States: a case report on acute rheumatic fever.Journal of medical case reports · 2026Article
- Probiotics and Antibiotics: From Empirical Practice to a Biological Rationale for Targeted Choice During Antibiotic Therapy.Microorganisms · 2026Review
- Acute Rheumatic Fever Beyond Childhood: Case Series of Adult Recurrence and Atypical Manifestations.Cureus · 2026Article
- Global disparities in the detection and management of rheumatic heart disease in pregnancy across endemic settings.Frontiers in surgery · 2026Review
- Review
- Integrating secondary prevention of rheumatic heart disease into the primary healthcare system in Northern Uganda.BMJ global health · 2025Article
- Diagnostic test accuracy of simplified algorithms for diagnosing acute rheumatic fever: a systematic review.Communications medicine · 2025Article
- The burden of rheumatic heart disease and issues affecting the provision of care in Malawi: A scoping review.PLoS neglected tropical diseases · 2025Article
- Shortages of benzathine benzylpenicillin G in Australia highlight the need for new sovereign manufacturing capability.The Medical journal of Australia · 2025Article
- Article
- Acute rheumatic fever presenting as fulminant myocarditis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2024Article
- Lifelong Rheumatic Heart Disease: Evolution and Need for Tailored Care.JACC. Case reports · 2024Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeople with a history of rheumatic fever are at high risk of recurrent attacks of rheumatic fever and developing rheumatic heart disease following a streptococcal throat infection. Giving penicillin to these people can prevent recurrent attacks of rheumatic fever and subsequent rheumatic heart disease. However, there is no agreement on the most effective method of giving penicillin.
objectivesTo assess the effects of penicillin compared to placebo and the effects of different penicillin regimens and formulations for preventing streptococcal infection and rheumatic fever recurrence. SEARCH STRATEGY: We searched the Controlled Trials Register (Cochrane Library Issue 2, 2001), MEDLINE (1997 to July 2000), EMBASE (1998 to July 2000), reference lists of articles and we contacted experts in the field. SELECTION CRITERIA: Randomised and quasi-randomised studies comparing (i) penicillin with control, (ii) oral with intramuscular penicillin (iii) 2- or 3-weekly with 4-weekly intramuscular penicillin in patients with previous rheumatic fever. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed trial quality and extracted data. MAIN
resultsNine studies were included (n=3008). Data were not pooled because of heterogeneity. Overall, the methodological quality of included studies was poor. Three trials (n= 1301) compared penicillin with control. Only one of three studies showed that penicillin reduced rheumatic fever recurrence (RR 0.45, 95% CI 0.22 to 0.92) and streptococcal throat infection (RR 0.84, 95% CI 0.72 to 0.97). Four trials (n=1098) compared intramuscular with oral penicillin and all showed that intramuscular penicillin reduced rheumatic fever recurrence and streptococcal throat infections compared to oral penicillin. One trial (n= 360) compared 2-weekly with 4-weekly intramuscular penicillin. Penicillin given every two-weeks was better at reducing rheumatic fever recurrence (RR 0.52, 95% CI 0.33 to 0.83) and streptococcal throat infections (RR 0.60, 95% CI 0.42 to 0.85). One trial (n= 249) showed 3-weekly intramuscular penicillin injections reduced streptococcal throat infections (RR 0.67, 95% CI 0.48 to 0.92) compared to 4-weekly intramuscular penicillin. REVIEWER'S
conclusionsIntramuscular penicillin seemed to be more effective than oral penicillin in preventing rheumatic fever recurrence and streptococcal throat infections. Two-weekly or 3-weekly injections appeared to be more effective than 4-weekly injections. However, the evidence is based on poor quality of trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.